Anna Chokina has been appointed as CEO of Cellular Goods following the launch of its new product range.
Chokina is succeeding Alexis Abraham who will now act as chief strategy officer with both appointments coming into effect from 6 December, 2021. Abraham will now be focusing on brand positioning and product development and remains a director on Cellular Goods’ board.
Peter Wall, chairman of Cellular Goods, said: “On behalf of the Board, I would like to thank Alexis for his hard work and ongoing commitment to Cellular Goods. Under his leadership the company has established a strong foundation as the first pure-play consumer cannabinoid brand to list on the LSE and successfully launched its inaugural product ranges just nine months after the start-up of commercial operations.
“Anna’s appointment heralds an exciting new chapter for Cellular as the company enters its revenue-generating phase and her deep expertise will help guide the future direction of the company. She has a proven track record with several global consumer brands and is the right leader to drive Cellular to the next level. Our ambition for the company is significant and clear and the entire company and the board look forward to working with her.”
Chokina has spent more than 20 years in senior-level roles in the consumer goods industry, having previously acted as vice president of Global Colour Cosmetics, Global Face Care and Personal Care at Avon where. During this time Chokina launched Avon’s first-ever lines of CBD-based products. She has also spent time as general manager of L’Oreal Paris for Russia.
Chokina commented: “I am excited to join Cellular Goods at this point of development, following the launch of its inaugural product range. I am proud to be joining a company that produces high-quality, research-backed products and that champions the use of innovative and sustainable lab-made cannabinoids.
“I believe there is a significant opportunity to harness the strengths of the business to successfully deliver the planned product expansion and brand elevation. I am looking forward to working with the whole Cellular team to build a strong business for our customers, our employees, our partners and to deliver long-term value for our shareholders.”
“I am immensely proud to have been able to realise our growth strategy in a far shorter time period than anticipated and am delighted to pass the baton to Mrs Chokina. Last week we launched our inaugural products and Cellular Goods is ideally positioned to become the leading player in the space,” added Abraham.
Cannaray: “We aim to become the leading medical cannabis player in Europe”
Cannaray recently closed a £10 million funding round to expand its medical cannabis arm.
Cannabis Wealth caught up with Cannaray CEO Scott Macguire to hear about the company’s plans to expand its medical cannabis division following a £10 million funding round earlier this year.
In April this year, Cannaray closed a £10 million funding round that included a significant investment from Channel 4 Ventures. Cannaray believes the investment was a first of its kind in Europe for a major TV broadcaster.
“We were delighted to close on an amount above our initial targets, considering the difficult capital markets,” Cannaray CEO Scott Macguire told Cannabis Wealth.
“It was a great sign of confidence in the company to see existing investors come back in for this round as well as welcoming major new investors such as Channel 4 Ventures. TV advertising has taken Cannaray to new heights, so we’re thrilled to be able to partner with Channel 4 to continue to drive rapid growth of the brand.”
Other participants in the round include Three Bridges Private Capital, Alpha Blue Ocean and a mix of new and follow-on private investors.
Cannaray’s group of companies spans both medical cannabis and CBD wellness brands. Its CBD brand is already well-established in the UK. In the summer of 2021, Cannaray launched the UK’s first major brand campaign for CBD on TV. In addition to a high-performing B2C site, the brand is also stocked on Amazon and in over 1500 retail outlets across the UK including Tesco, Superdrug, ASDA, Waitrose and Harrods.
Now, the company is turning its focus to medical cannabis. The majority of the recent raise will be channelled into Cannaray’s medical division Therismos as it seeks to scale and expand its footprint in Germany and the UK.
“Our aim is to become the leading medical cannabis player in Europe,” Macguire said. “We have significantly strengthened our position over the last year to cover supply, distribution and prescription of cannabis-based medical products (CBMP) across Europe.”
In Germany, Cannaray recently embarked on a “transformational” partnership with Alliance Healthcare Deutschland – a division of Walgreens Boots Alliance – to help establish the brand’s presence in the German market.
The German federal government announced it would be putting plans in motion to legalise adult-use cannabis in November 2021. After a number of delays, Germany’s health minister Karl Lauterbach announced that the legal process for cannabis legalisation would begin this summer.
“[Germany] is the largest CBMP market in Europe and where AHG has a significant footprint,” Macguire added.
“Our medical cannabis division Therismos will be activating the partnership with AHG with the aim of becoming one of the leading providers of CBPM in a market growing at 13 per cent year-on-year.
“Our pipeline plans include product innovation, new presentations [and] galenic forms and novel technologies that will step change a market that is in its creation phase.”
Cannaray is also looking to tap into the medical cannabis sector in the UK. While only 30,000 patients have access to a medical cannabis prescription currently, there is huge potential for growth with an estimated 1.4 million people self-medicating with illicit cannabis, according to YouGov statistics.
The firm will soon be opening a medical cannabis clinic with the help of leading pain specialists in the UK.
“The UK is our second priority since this market represents the greatest growth opportunity in Europe,” Macguire said. “The UK is a small market relative to Germany and even smaller still when compared to North America.
“The prevailing challenge in the UK is the cost of the medication, as the NHS does not cover the cost of the medication. Estimates put the cost per patient per year at over £3,500. There will be a cap on the growth of CBPM in the UK until the NHS covers the cost and GPs are allowed to prescribe.
Macguire said Cannaray is now exploring additional acquisitions in its efforts to position the company as a leader in the European medical cannabis market.
Curaleaf appoints new chief people officer
Tyneeha Rivers will take on the role.
Curaleaf Holdings has appointed Tyneeha Rivers to the role of chief people officer (CPO) – a new position within the company.
Rivers will be taking on the role following the announcement of Matt Darin being named CEO. Darin will be replacing Joe Bayern, who will be launching a new CPG-focused division of the company.
CEO of Curaleaf, Darin, commented: “This is an incredibly exciting time for Tyneeha to join us and I am thrilled to welcome her to my executive leadership team.
“With over twenty years of global Human Resources expertise in senior positions for distinguished organisations, Tyneeha has a proven track record of building winning team cultures that positively impact business results.
“This is a critical focus for us at Curaleaf as we move the company forward. My goal is not only to be the leading global cannabis company, but also the place to be for the most talented, motivated, and passionate team members in the industry, bar none.”
Rivers will lead the Curaleaf’s Human Resources department and help advance strategic HR operations, talent acquisition, talent management, diversity, equity and inclusion, leadership development, training programmes, employee relationship management, compensation and benefits, job design and succession planning.
Rivers stated: “I am honoured to join the Curaleaf team at this exciting time in the company’s evolution and rapid growth.
“Curaleaf has established itself as a leader in the cannabis space, not just in revenue or retail footprint, but in talent and commitment. I look forward to partnering with the entire Curaleaf team to continue focusing on strategic HR operations and the investment in the Company’s people, without whom this exponential growth would not be possible.”
Rivers brings over 20 years of experience in corporate human resources, leading HR for various prominent organisations such as Merrill Lynch, Morgan Properties, The Galman Group, Philadelphia 76ers, Harris Blitzer Sports & Entertainment, Greater Philadelphia YMCA, and most recently, CPO at Curio Wellness.
Rivers currently serves as board president of Second Chance Mission, an organisation established to help survivors of substance abuse, domestic violence, bullying, life-altering illness and other hardships.
Kendra Mark appointed as director of product at Tenacious Labs
Mark has a passion for health and wellness.
Kendra Mark is joining UK-based CBD company Tenacious Labs as its new director of product.
International consumer products group championing emerging plant-based ingredients, including CBD and Psilocybin, Tenacious Labs, has welcomed Mark to its team.
Mark joins Tenacious Labs with industry-leading expertise in new product development, significant experience in the CBD and hemp sector, and a passion for health and wellness.
COO of Tenacious Labs, Susie MacArthur, commented: “We are delighted to welcome Kendra to the Group. With considerable industry experience, both in senior leadership and new product development roles, her expertise will be invaluable as we look to scale up, launch our brands around the world, and become a leading consumer products group globally.
“We believe this is the start of a really exciting period for Tenacious Labs, and we’re pleased to have Kendra join us on our journey.”
Director of product at Tenacious Labs, Mark, commented: “I am hugely excited to join Tenacious Labs, a Group which I have admired for some time.
“Like me, the team have fantastic ambitions to create an industry-leading Group that harnesses the natural power of CBD and other emerging ingredients. I am looking forward to getting stuck in and doing what I love most: creating natural products that support the day-to-day wellbeing of consumers around the world.”
Mark most recently co-founded natureofthings, a wellness brand focusing on natural ingredients, minerals and elements, including hemp. She has also served as VP of product development at Hemp Depot, a specialist hemp wholesaler, and led 2Rise Naturals, a consumer brand specialising in high-quality CBD.
In her role at Tenacious Labs, Kendra will be responsible for creating unique and differentiated products across the Group’s portfolio of brands, such as Press Pause and HOO RAA.
Mark will also work closely with TL Manufacturing — Tenacious Labs’ wholly-owned production facility based out of Colorado, USA — to launch products in new and emerging categories. This will support the group’s broader strategic goal of becoming a leading consumer products group globally.
Kendra, who is based in Arizona, joins Tenacious Labs’ predominantly female management team, which includes its chief operations officer, Susie MacArthur; chief financial officer, Sally Hayes; and head of lifestyle brands, Dawn Fable, at the start of its next growth phase.
In addition to Mark’s role, the Group is also actively hiring for several new roles as it looks to scale up and launch its brands around the world.